Jazz Pharmaceuticals (NASDAQ:JAZZ) Reaches New 1-Year High on Analyst Upgrade

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) reached a new 52-week high on Wednesday after Royal Bank Of Canada raised their price target on the stock from $191.00 to $195.00. Royal Bank Of Canada currently has an outperform rating on the stock. Jazz Pharmaceuticals traded as high as $192.66 and last traded at $192.7220, with a volume of 1408011 shares trading hands. The stock had previously closed at $173.83.

JAZZ has been the subject of several other research reports. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research note on Monday, December 29th. Wells Fargo & Company increased their price objective on shares of Jazz Pharmaceuticals from $235.00 to $250.00 and gave the company an “overweight” rating in a research note on Wednesday. Robert W. Baird lifted their target price on shares of Jazz Pharmaceuticals from $160.00 to $209.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 18th. Bank of America upped their price target on shares of Jazz Pharmaceuticals from $263.00 to $275.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Morgan Stanley increased their price target on shares of Jazz Pharmaceuticals from $225.00 to $226.00 and gave the company an “overweight” rating in a research report on Wednesday. Fourteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $212.86.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 4,660 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $171.20, for a total value of $797,792.00. Following the completion of the sale, the chief accounting officer directly owned 7,012 shares of the company’s stock, valued at approximately $1,200,454.40. The trade was a 39.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Mary Elizabeth Henderson sold 2,238 shares of the business’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $169.51, for a total value of $379,363.38. Following the completion of the transaction, the senior vice president owned 19,508 shares of the company’s stock, valued at $3,306,801.08. This trade represents a 10.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals News Roundup

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Q4 results beat expectations — Jazz posted $6.64 EPS and $1.20B revenue, topping consensus and showing y/y revenue growth; investors view the print as confirmation of underlying demand. Earnings Call Summary
• Positive Sentiment: Company issued 2026 revenue guidance of $4.25B–$4.50B, in line with/near street expectations, reducing near‑term forecasting uncertainty and supporting the rally. Press Release
• Positive Sentiment: Strong product performance — Xywav ($1.7B, 12% y/y) and Epidiolex ($1.1B, 9% y/y) drove growth; Modeyso had a strong early launch ($37M in its first full quarter), supporting the top‑line beat. Product Sales Detail
• Positive Sentiment: Multiple analyst price‑target upgrades and bullish notes hit after the results (Bank of America to $275, Wells Fargo to $250, Morgan Stanley to $226, RBC to $195), amplifying buying interest from institutions and momentum traders. Analyst Upgrades
• Positive Sentiment: Pipeline progress: company expects to complete an sBLA submission for zanidatamab under RTOR in 1Q26 for HER2+ first‑line GEA — a successful filing/approval could materially expand oncology revenue over time. Pipeline & Guidance
• Neutral Sentiment: Management released the earnings slide deck and full call transcript — useful for digging into margin drivers, product cadence and assumptions behind 2026 guidance. Earnings Transcript
• Negative Sentiment: Profitability nuance: the company still showed a negative net margin in the quarter (impacted by non‑operating items and costs), so investors should watch whether earnings quality improves as 2026 progresses. Earnings Metrics
• Negative Sentiment: Valuation and risk: JAZZ trades at a relatively elevated P/E and carries leverage (debt/equity ~1.1); while analysts raised targets, some (RBC) show limited near‑term upside versus the current price — consider valuation vs. growth when sizing positions. Analyst Context

Hedge Funds Weigh In On Jazz Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Kennedy Capital Management LLC bought a new stake in Jazz Pharmaceuticals in the second quarter valued at about $1,100,000. Wedge Capital Management L L P NC acquired a new position in shares of Jazz Pharmaceuticals in the 3rd quarter worth approximately $27,834,000. Essex Investment Management Co. LLC bought a new stake in shares of Jazz Pharmaceuticals in the 3rd quarter valued at approximately $2,697,000. Sequoia Financial Advisors LLC acquired a new stake in shares of Jazz Pharmaceuticals during the 3rd quarter valued at approximately $605,000. Finally, Aberdeen Group plc acquired a new stake in shares of Jazz Pharmaceuticals during the 3rd quarter valued at approximately $8,629,000. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Price Performance

The stock has a market capitalization of $11.96 billion, a P/E ratio of -32.97, a PEG ratio of 0.93 and a beta of 0.26. The company has a 50 day moving average of $168.72 and a 200-day moving average of $150.60. The company has a quick ratio of 1.44, a current ratio of 1.65 and a debt-to-equity ratio of 1.09.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Tuesday, February 24th. The specialty pharmaceutical company reported $6.64 earnings per share for the quarter, topping analysts’ consensus estimates of $6.49 by $0.15. Jazz Pharmaceuticals had a negative net margin of 8.35% and a positive return on equity of 7.03%. The company had revenue of $1.20 billion for the quarter, compared to analysts’ expectations of $1.17 billion. During the same period in the prior year, the company earned $6.51 earnings per share. The firm’s revenue was up 8.1% compared to the same quarter last year. Sell-side analysts predict that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.